Common diabetes drug may boost survival in septic shock
NCT ID NCT07591402
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked back at medical records of 2,740 adults with type 2 diabetes who were admitted to the ICU for septic shock, a life-threatening infection. Researchers wanted to see if those who were already taking metformin (a standard diabetes pill) before getting sick had a lower chance of dying within 30 days. The goal is to understand if metformin offers extra protection beyond controlling blood sugar.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for D003924 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Unité de Recherche Clinique Paris Saclay
Paris, 75010, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Daily pill could offer new hope for weight loss in east asian adults
- Blood test could predict who faces rapid kidney decline in diabetes
- Blood test may predict kidney decline in diabetes — a large trial investigates
- Hormone clue may unmask kidney danger in diabetes
- Can a single pill tackle both fatty liver and diabetes?
- Does when you eat carbs and protein reshape blood sugar control?